Characterization of the human immune response to the UK anthrax vaccine.
The anthrax bipartite lethal toxin (protective antigen (PA) and lethal factor (LF))-specific antibody responses of humans receiving the UK licensed anthrax vaccine were determined. The PA-specific IgG response peaked two weeks post immunization and fell back to pre-boost levels by week 12. The heterogeneity of the host population modulated the extent of the PA-specific antibody response. Significantly lower levels of LF-specific antibodies were also detected. Vaccinated individuals recognized the same PA epitope as the protective mouse lethal toxin neutralizing monoclonal 2D3 suggesting that this may also be a target for human protection.
Baillie
Les
L
Biodefense Vaccines, Biological Defense Research Directorate, Naval Medical Research Center, Silver Spring, MD 20910-7500, USA. bailliel@mmrc.navy.mil
Townend
Tim
T
Walker
Nicki
N
Eriksson
Ulla
U
Williamson
Diane
D
D000328:Adult; D000881:Anthrax / Q000517:prevention & control; D022122:Anthrax Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D000907:Antibodies, Bacterial / Q000097:blood; D000918:Antibody Specificity; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology*; D001408:Bacillus anthracis / Q000276:immunology*; D001427:Bacterial Toxins / Q000235:genetics / Q000276:immunology*; D018604:Epitope Mapping; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008875:Middle Aged; D011994:Recombinant Proteins; D006113:United Kingdom; D014611:Vaccination
D022122:Anthrax Vaccines; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D007074:Immunoglobulin G; D011994:Recombinant Proteins; C030325:anthrax toxin